Millions of individuals rely on effective medications to manage diseases like cancer and diabetes. For those with chronic myeloid leukemia (CML), advancements in treatment selection could ...

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers.

Novartis’ first-in-class STAMP inhibitor Scemblix could be headed for use earlier in the treatment pathway for chronic myeloid leukaemia (CML). At the ASCO congress in Chicago today, the results ...

After being diagnosed with chronic myeloid leukemia, graphic designer Aaron von Freter was able to participate in a clinical trial that offered him hope of being cured. When Aaron von Freter learned ...

Researchers are exploring new treatment options for chronic myeloid leukemia (CML). Many treatments that have recently been studied or are currently under investigation are targeted therapy drugs.

or chronic myelogenous leukemia, you know that your bone marrow is making cells from early versions of certain blood cells. Your treatment will be geared toward controlling this overproduction ...

Frequent monitoring of blood counts is required while on therapy. Initial treatment of CML patients with hydroxyurea is usually a daily dose of 1-4 grams, depending on the white blood count ...

Melvin Mann, diagnosed with chronic myeloid leukemia in 1994, participated in a clinical trial for Imatinib that extended his ...

“CML is a form of cancer that many people live with for a long time without knowing it. Symptoms can be absent for several years before the patient becomes visibly ill," Dr. Astrid S. de Wijn. Stem ...

The only commercialized Ascentage product is olverembatinib, a drug approved in China as a treatment for certain patients with chronic myeloid leukemia (CML). This drug is a small molecule ...

Prognostic determinants for CML patients in the context of a growing array of treatment options will then be discussed, and an algorithm for treatment will be proposed. Finally, promising agents ...